Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cycloxygenase inhibition

Table 3 Results of ⁵¹Cr autologous platelet survival studies in 4 controls (Group I), in 3 cases of thrombocytosis in chronic myeloid leukemia and 3 cases of reactive thrombocytosis (Group II), in 6 cases of asymptomatic thrombocythemia in essential thrombocythemia, myelofibrosis and polycythemia vera (Group III), and in 8 cases of thrombocythemia in essential thrombocythemia, myelofibrosis and polycythemia vera complicated by erythromelalgia (Group IV)

Patient group	Diagnosis	Platelet, × 10/L	E	T1/2 (d)	Mean life span	Maximal life span
I	210		No	3.6	5.4	9.9
	181		No	4.2	9.0	9.1
	193		No	3.9	7.1	7.8
	138		No	3.7	6.0	8.8
Mean	180			3.9	6.9	8.9
II	722	CML	No	4.0	8.6	8.2
	1487	CML	No	3.9	7.6	7.3
	2244	CML	No	4.0	7.4	7.7
	1015	RT	No	4.0	6.7	8.7
	736	RT	No	4.0	6.6	7.8
	866	RT	No	4.9	9.7	9.2
Mean	1178			4.1	7.9	8.2
III	1722	ET	No	3.4	5.9	6.8
	1167	ET	No	3.0	4.6	7.3
	511	MF	No	3.1	4.5	8.8
	935	PV	No	3.8	6.2	9.0
	506	PV	No	3.5	5.8	8.8
	614	PV	No	3.3	5.7	7.5
Mean	918			3.3	5.4	8.0
IV	666	ET	Yes	2.1	2.9	6.4
	637	ET	Yes	2.6	4.0	6.8
	1018	ET	Yes	2.7	4.2	7.2
	539	MF	Yes	1.8	2.6	6.1
	489	PV	Yes	2.7	4.0	7.9
	1028	PV	Yes	2.5	1.7	7.3
	1036	PV	Yes	2.0	3.4	5.6
	1180	PV	Yes	3.1	6.0	5.8
Mean	824			2.4	3.6	6.6

CML: Chronic myeloid leukemia; RT: Reactive thrombocytosis; ET: Essential thrombocythemia; PV: Polycythemia vera; MF: Myelofibrosis.